Second Sight Medical Products (NASDAQ: EYES) and Cyberonics (NASDAQ:CYBX) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, valuation, profitability, risk, dividends, earnings and institutional ownership.

Earnings and Valuation

This table compares Second Sight Medical Products and Cyberonics’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio EBITDA Earnings Per Share Price/Earnings Ratio
Second Sight Medical Products $5.14 million 10.72 -$32.85 million ($0.72) -1.35
Cyberonics N/A N/A N/A N/A N/A

Cyberonics has higher revenue, but lower earnings than Second Sight Medical Products.

Institutional and Insider Ownership

15.3% of Second Sight Medical Products shares are owned by institutional investors. 34.7% of Second Sight Medical Products shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.


This table compares Second Sight Medical Products and Cyberonics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Second Sight Medical Products -646.89% -168.49% -129.48%
Cyberonics 15.33% 17.49% 15.23%

Analyst Ratings

This is a summary of current ratings and price targets for Second Sight Medical Products and Cyberonics, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Second Sight Medical Products 0 0 1 0 3.00
Cyberonics 0 0 0 0 N/A

Second Sight Medical Products presently has a consensus target price of $5.00, indicating a potential upside of 415.46%. Given Second Sight Medical Products’ higher possible upside, analysts plainly believe Second Sight Medical Products is more favorable than Cyberonics.


Second Sight Medical Products beats Cyberonics on 5 of the 8 factors compared between the two stocks.

About Second Sight Medical Products

Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. The Company’s Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The Argus II System works by converting video images captured by a miniature camera housed in a patient’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina.

About Cyberonics

Cyberonics, Inc. is a medical device company. The Company is engaged in the design, development, sale and marketing of medical devices for epilepsy, depression and heart failure. Its seminal product, the VNS Therapy System, is an implantable device that provides neuromodulation therapy for the treatment of drug-resistant epilepsy and treatment-resistant depression (TRD). The Company’s VITARIA System is an implantable device that provides a form of neuromodulation therapy for the treatment of chronic heart failure (CHF). The VNS Therapy System and its VITARIA System include an implantable pulse generator to stimulate the vagus nerve; a lead that conducts current pulses from the pulse generator to the vagus nerve; a surgical instrument to assist with the implant procedure; equipment to enable the treating physician to set the pulse generator stimulation parameters for the patient; instruction manuals, and in the VNS Therapy System, magnets to suspend or induce stimulation manually.

Receive News & Ratings for Second Sight Medical Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products Inc. and related companies with's FREE daily email newsletter.